<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/091A7281-194A-4C7B-8E9A-0CEB4FEE954B"><gtr:id>091A7281-194A-4C7B-8E9A-0CEB4FEE954B</gtr:id><gtr:name>Faculty of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2D53F5AB-1256-4813-BF74-4AFDE1870B96"><gtr:id>2D53F5AB-1256-4813-BF74-4AFDE1870B96</gtr:id><gtr:firstName>Adam</gtr:firstName><gtr:otherNames>Murdin</gtr:otherNames><gtr:surname>Sillito</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7A9DD464-06E6-4AAC-B842-894B1934086B"><gtr:id>7A9DD464-06E6-4AAC-B842-894B1934086B</gtr:id><gtr:firstName>George</gtr:firstName><gtr:otherNames>W</gtr:otherNames><gtr:surname>Aylward</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D7E9F4B2-DD53-4EBE-B00A-868618120331"><gtr:id>D7E9F4B2-DD53-4EBE-B00A-868618120331</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>McLaren</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601588"><gtr:id>5CFCF188-6E9B-44B4-BC05-B2DEF1307F0C</gtr:id><gtr:title>Experimental choroidal surgery for age-related macular degeneration</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601588</gtr:grantReference><gtr:abstractText>Age-related macular degeneration is the commonest cause of blindness in the UK and most people have an elderly relative who is affected by the disease to some extent. Macular degeneration leads to a burning out of the central part of the vision, leaving patients unable to read or recognise people?s faces. The retina is made up of a thin delicate sensory layer that is easily damaged, lined and protected by a more robust layer known as the choroid. This is analogous to an inner tube inside a tyre. Macular degeneration begins in the choroid (tyre) layer, but over a period of years gradually erodes through to damage the retina (inner tube), at which point vision is lost. The aim of our research is to develop an operation to move the degenerating choroid away from the central retina before it is irreversibly damaged. We propose to do this by rotating a large disc of the choroid layer after lifting up the retina. This will move the diseased choroid away from the fovea (the sensitive central part of the retina) to another part in the peripheral retina where vision loss will be barely noticeable. The fovea will thus be provided with relatively healthy choroid, which may set the degeneration back many decades. The surgery is performed from within the eye and is extremely challenging, but instruments developed recently have made it easier. We have already completed one trial with patients in our hospital and showed that this technique works well in principle. We have however discovered that we need to slide a much larger choroid layer and in such a way that preserves a blood vessel underneath. We have devised a means of doing this, but the surgery is quite different to anything we have done before and we therefore need to validate its effects in an animal model before proceeding to another clinical trial. Ethically we must be sure that there are no unexpected problems with the surgery before recommending it to our patients.</gtr:abstractText><gtr:technicalSummary>Age-related macular degeneration (AMD) causes blindness in thousands of people in the UK and its prevalence is increasing. AMD is believed to represent a chronic inflammation in the retinal pigment epithelium (RPE) and choroid layers of the retina. The inflammation is focussed on the central macula area and, over time, the inflammation breaks through to destroy the fovea and surrounding neurosensory retina with haemorrhage and fibrosis. Generally only the central area of RPE-choroid is affected by AMD, but this is the most vital part for vision. New injectable antibody treatments are being developed, but these are not applicable to all AMD patients, only combat the late stages of the disease and require repeated administration. Our research is to develop an operation to replace the diseased subfoveal RPE-choroid in one go and before the fovea is irreversibly damaged. We recently completed a clinical trial in 12 patients and showed that RPE-choroid taken from the equator of the eye (where it is virtually unaffected by AMD) can support vision when slid under the fovea. In that study the RPE-choroid was a free tissue graft and re-establishment of blood supply was erratic. We therefore propose a second trial to transplant an RPE-choroid graft, but in this case pedicled on the lateral long posterior ciliary artery (LPCA). The graft would remain vascularised throughout the procedure. We are proposing to move a relatively large plate of tissue under the retina within the eye and this has never been done before. We therefore need first to be sure that the operation is safe before performing it on patients. In particular, we need to know if the blood supply within the graft can be sustained during the movement and whether or not the overlying retina is damaged by the surgery. We therefore propose to test the operation in an animal model with a similar LPCA choroidal vascular system to humans. We will assess blood flow through the graft by angiography and examine the overlying fovea anatomically and functionally. We believe this will provide us with the information we require in order to continue with the next step of our clinical trial.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>421876</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology UCL</gtr:department><gtr:description>Long term follow-up of experimental choroidal surgery</gtr:description><gtr:id>B92BF8EE-FB8A-48B1-9BDE-B99E84DB80F9</gtr:id><gtr:impact>PubMed Publications: 19459869, 17600111, 17324698</gtr:impact><gtr:partnerContribution>1. Further publications on the surgical technique in patients 2. Applications to developing stem cell therapies for retinal diseases</gtr:partnerContribution><gtr:piContribution>1. I developed a technique for surgery in patients with macular degeneration, with Lyndon da Cruz and Bill Aylward as co-investigators. 2. We used a new technique of assessing retinal function in patients undergoing transplantation (Lyndon da Cruz as Principal Investigator. 3. We expored the role of retinal stem cells from the pig eye (Robin Ali as co-investigator).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Ophthalmology UCL</gtr:department><gtr:description>New choroidal surgery technique for uveal effusion syndrome</gtr:description><gtr:id>B28AE5BF-31C8-4BBE-B839-61D45CFB9059</gtr:id><gtr:impact>PubMed Publication: 19130073</gtr:impact><gtr:partnerContribution>We have developed a new surgcial technique for a sight threatening disease that otherwise has a poor prognosis.</gtr:partnerContribution><gtr:piContribution>I developed this technique as lead investigator with two junior surgical collagues at Moorfields Eye Hospital.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Faculty of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>Gene therapy for choroideraemia - a Phase 1 clinical trial</gtr:description><gtr:id>9C004721-AF72-4FF4-BC2D-4A94896BEC21</gtr:id><gtr:impact>1. GTAC0171 application submitted on 9 December 09 - provisional approval given. 2. Publication on choroideraemia submitted to IOVS (under review) 3. The surgical technique developed in this project is directly relevant to the design of the clinical trial 4. A grant of &amp;pound;1.2M was awarded to me as PI (with M Seabra as co-applicant) in order to start the clinical trial.</gtr:impact><gtr:partnerContribution>Successful application to GTAC for clinical trial approval</gtr:partnerContribution><gtr:piContribution>I am leading the clinical trial application with Prof Miguel Seabra as co-applicant. A Health Innovation Challenge Fund grant application is currently under review.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Television and radio interviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>084F0A2B-13FB-4161-83F1-236CBEA86B82</gtr:id><gtr:impact>Extensive media coverage over the last 7 years of our research work in retinal gene therapy and bionic eyes - see link: www.ndcn.ox.ac.uk/research/clinical-ophthalmology-research-group/research-group-information/in-the-news

Public communication</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.ndcn.ox.ac.uk/research/clinical-ophthalmology-research-group/research-group-information/in-the-news</gtr:url><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Roadshow</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5A2EC0E2-13CC-43FC-A4D9-8E5BF6314BB6</gtr:id><gtr:impact>Over 50 pupils and education representatives attended the MRC Roadshow event

Guidance for clinician scientists.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant: Gene therapy for blindness caused by choroideraemia - a Phase I clinical trial</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Health Innovation Challenge Fund (HICF)</gtr:fundingOrg><gtr:id>07E8F5D5-4A6A-40B5-B6ED-2CC2F1DC01D7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant: Gene therapy for Stargardt Disease</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>ADF4EA07-E320-4B06-A62A-1D40B700CA23</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Ophthalmology Major Project Grant: Developing rod transplantation as a means of sustaining cones in rod-cone dystrophies</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>The Royal College of Surgeons of Edinburgh</gtr:fundingOrg><gtr:id>9DF0B3F9-7B4A-4799-B952-5678C3FDCA16</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London</gtr:department><gtr:description>NIHR BRC Ophthalmology Theme: Age related macular degeneration</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>8D204F8C-3ED4-4782-88B2-77F4DA3A4F11</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>97000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship: Cone gene therapy for retinitis pigmentosa</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>C72692D4-DA13-4610-9D6F-6124AF74E4DF</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>245000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship: Developing melanopsin gene therapy to restore vision to the blind retina</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>BB645D1B-1962-4983-8996-242897D340F6</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>179000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Training Fellowship: Exploring gene therapy and stem cell approaches to preserve cones in retinitis pigmentosa</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>4A444C70-287A-49E5-89A2-3ECEA844502B</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Committee on Health and Environmental Risks (SCHER) of the European Commission - Working Group on &amp;quot;The need for non human primates in biomedical research, production and testing of products and devices&amp;quot;</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>2C38A018-2512-4621-AF93-A3EAB1500D05</gtr:id><gtr:impact>Our contributions based on our experience with applied primate research helped the Working Group to understand the need for the use of non-human primates in this field. It also helped prevent a possible ban on the use of non-human primates in EU.</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome.</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>BBA88CFE-EC07-437E-828A-41362A2D2DBE</gtr:id><gtr:impact>Several retinal surgeons have since made contact to find out more about the technique</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A UK-based Phase 1 clinical trial of the AAV.REP1 gene therapy, sponsored by the University of Oxford and funded by the Health Innovation Challenge Fund, a joint venture of the Wellcome Trust and the Department of Health.</gtr:description><gtr:id>94B50CCB-7F93-41CF-8FD4-3D8B3E3A3FA2</gtr:id><gtr:impact>In view of the safety and efficacy of the AAV.REP1 vector that has been demonstrated in this Phase 1 clinical trial and subsequent Phase 2 clinical trials, a pivotal Phase 3 clinical trial of the AAV.REP1 gene therapy is scheduled to commence in the latter half of 2016.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>UK-based Phase 1 clinical trial of a gene therapy for choroideremia</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:url>http://www.ox.ac.uk/news/2014-01-16-gene-therapy-trial-shows-promise-type-blindness</gtr:url><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C442C2A-06B4-4F6A-B2DC-5AA2B7BFBDBC"><gtr:id>3C442C2A-06B4-4F6A-B2DC-5AA2B7BFBDBC</gtr:id><gtr:title>Stem cell therapy and the retina.</gtr:title><gtr:parentPublicationTitle>Eye (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-222X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7ECDA408-EA49-41F4-A0AB-3DC41EE150D9"><gtr:id>7ECDA408-EA49-41F4-A0AB-3DC41EE150D9</gtr:id><gtr:title>In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64f94d6bab9e907972bd284e2e8d429c"><gtr:id>64f94d6bab9e907972bd284e2e8d429c</gtr:id><gtr:otherNames>Buch PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D0774352-0F51-4A21-90BD-A074474FA205"><gtr:id>D0774352-0F51-4A21-90BD-A074474FA205</gtr:id><gtr:title>Cell transplantation strategies for retinal repair.</gtr:title><gtr:parentPublicationTitle>Progress in brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26d7dfcefdd053a52abac2493b7dca32"><gtr:id>26d7dfcefdd053a52abac2493b7dca32</gtr:id><gtr:otherNames>West EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0079-6123</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B636F5A-E0C0-477A-8967-35F557BBCB1B"><gtr:id>1B636F5A-E0C0-477A-8967-35F557BBCB1B</gtr:id><gtr:title>The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e801d8829e8c609f13c10ef39dbe2ab"><gtr:id>5e801d8829e8c609f13c10ef39dbe2ab</gtr:id><gtr:otherNames>Luhmann UF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/239E270B-096F-465A-97BF-E857BD4C2003"><gtr:id>239E270B-096F-465A-97BF-E857BD4C2003</gtr:id><gtr:title>CNTF gene transfer protects ganglion cells in rat retinae undergoing focal injury and branch vessel occlusion.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E87EC805-2D9A-46E5-AA77-666BA0C129F8"><gtr:id>E87EC805-2D9A-46E5-AA77-666BA0C129F8</gtr:id><gtr:title>AAV-mediated gene transfer of human X-linked inhibitor of apoptosis protects against oxidative cell death in human RPE cells.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a9fe7cbeb8322eefa5c90912559c858"><gtr:id>8a9fe7cbeb8322eefa5c90912559c858</gtr:id><gtr:otherNames>Shan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/93DB479F-09CB-4FB5-B481-02D3ECE0A58F"><gtr:id>93DB479F-09CB-4FB5-B481-02D3ECE0A58F</gtr:id><gtr:title>Uveitic glaucoma and Rosai-Dorfman disease (sinus histiocytosis).</gtr:title><gtr:parentPublicationTitle>Ocular immunology and inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0927-3948</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/54B40062-C8AA-4B29-A4DD-23FDC646613F"><gtr:id>54B40062-C8AA-4B29-A4DD-23FDC646613F</gtr:id><gtr:title>Macular function assessed by microperimetry in patients with enhanced S-cone syndrome.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/af02345d132a365350db2e8b295f8da4"><gtr:id>af02345d132a365350db2e8b295f8da4</gtr:id><gtr:otherNames>Sohn EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2419E9CB-E00B-4555-BEF2-AE8C075A0781"><gtr:id>2419E9CB-E00B-4555-BEF2-AE8C075A0781</gtr:id><gtr:title>Isolation and characterisation of neural progenitor cells from the adult Chx10(orJ/orJ) central neural retina.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9ddaadbfdd7d61fd52e75561dd43de99"><gtr:id>9ddaadbfdd7d61fd52e75561dd43de99</gtr:id><gtr:otherNames>Kokkinopoulos I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9126C90-E66F-4040-A9B1-553C11C1CD6A"><gtr:id>C9126C90-E66F-4040-A9B1-553C11C1CD6A</gtr:id><gtr:title>Retinal repair by transplantation of photoreceptor precursors.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31D29D37-7B9C-463A-A227-B7869AC9E514"><gtr:id>31D29D37-7B9C-463A-A227-B7869AC9E514</gtr:id><gtr:title>Long-term visual and microperimetry outcomes following autologous retinal pigment epithelium choroid graft for neovascular age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Clinical &amp; experimental ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b4d7dce62f65fea9123090079f2cf76"><gtr:id>0b4d7dce62f65fea9123090079f2cf76</gtr:id><gtr:otherNames>Chen FK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1442-6404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91925D32-DC94-4DCA-837A-18FB016441D8"><gtr:id>91925D32-DC94-4DCA-837A-18FB016441D8</gtr:id><gtr:title>Biometry and formula accuracy with intraocular lenses used for cataract surgery in extreme hyperopia.</gtr:title><gtr:parentPublicationTitle>American journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0002-9394</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30D38685-4F2E-4FB6-9564-42B0093FC1B4"><gtr:id>30D38685-4F2E-4FB6-9564-42B0093FC1B4</gtr:id><gtr:title>Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E81A234-9E01-4971-8065-5F58DFB2EF96"><gtr:id>3E81A234-9E01-4971-8065-5F58DFB2EF96</gtr:id><gtr:title>Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome.</gtr:title><gtr:parentPublicationTitle>Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab36f7db60c01e0cc6703482dd21cea"><gtr:id>4ab36f7db60c01e0cc6703482dd21cea</gtr:id><gtr:otherNames>Sabrosa NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0721-832X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34673C87-CDFA-4A6C-8838-AB2A16A4FEB1"><gtr:id>34673C87-CDFA-4A6C-8838-AB2A16A4FEB1</gtr:id><gtr:title>Sources of retinal pigment epithelium (RPE) for replacement therapy.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8033763ccfe8bc587cd808477d8fa410"><gtr:id>8033763ccfe8bc587cd808477d8fa410</gtr:id><gtr:otherNames>Lee E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E067FFF2-2F7B-4B6D-9880-C5AE3674F7CC"><gtr:id>E067FFF2-2F7B-4B6D-9880-C5AE3674F7CC</gtr:id><gtr:title>Implantation of the black diaphragm intraocular lens in congenital and traumatic aniridia.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9275c4facdb2dff3b3c959f26500a05f"><gtr:id>9275c4facdb2dff3b3c959f26500a05f</gtr:id><gtr:otherNames>Aslam SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9E21B31C-DB1A-4C76-83B6-69F4870FB4CD"><gtr:id>9E21B31C-DB1A-4C76-83B6-69F4870FB4CD</gtr:id><gtr:title>An analysis of retinal gene therapy clinical trials.</gtr:title><gtr:parentPublicationTitle>Current opinion in molecular therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-8431</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/558EDE93-E58E-40CE-879B-4671BE292B9D"><gtr:id>558EDE93-E58E-40CE-879B-4671BE292B9D</gtr:id><gtr:title>Effective gene therapy with nonintegrating lentiviral vectors.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/20625304df172be230ab164b5464dd32"><gtr:id>20625304df172be230ab164b5464dd32</gtr:id><gtr:otherNames>Y??ez-Mu?oz RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C3DC661-5DA2-435A-B70B-4A2055CDCCC5"><gtr:id>0C3DC661-5DA2-435A-B70B-4A2055CDCCC5</gtr:id><gtr:title>Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina.</gtr:title><gtr:parentPublicationTitle>Cell transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00ccfd6d705dd27d9f8e807d299400ce"><gtr:id>00ccfd6d705dd27d9f8e807d299400ce</gtr:id><gtr:otherNames>Pearson RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0963-6897</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EEE2BB9A-7AD8-4DAB-B67A-21583F65BD29"><gtr:id>EEE2BB9A-7AD8-4DAB-B67A-21583F65BD29</gtr:id><gtr:title>ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ab770da379674446271c8bfedb17ffa3"><gtr:id>ab770da379674446271c8bfedb17ffa3</gtr:id><gtr:otherNames>Burgess R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0EE757E7-0CDA-428F-A647-1B6F9B7576FF"><gtr:id>0EE757E7-0CDA-428F-A647-1B6F9B7576FF</gtr:id><gtr:title>EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0a3400abea0498c81fe87b128e20edb9"><gtr:id>0a3400abea0498c81fe87b128e20edb9</gtr:id><gtr:otherNames>Balaggan KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B2086CB-CBE3-499F-A9AA-DAFEA6A29025"><gtr:id>9B2086CB-CBE3-499F-A9AA-DAFEA6A29025</gtr:id><gtr:title>Arterial occlusion after scleral buckling.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9275c4facdb2dff3b3c959f26500a05f"><gtr:id>9275c4facdb2dff3b3c959f26500a05f</gtr:id><gtr:otherNames>Aslam SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0DF47792-6CD9-4E86-A5DA-028958D083C2"><gtr:id>0DF47792-6CD9-4E86-A5DA-028958D083C2</gtr:id><gtr:title>Long-term survival of photoreceptors transplanted into the adult murine neural retina requires immune modulation.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26d7dfcefdd053a52abac2493b7dca32"><gtr:id>26d7dfcefdd053a52abac2493b7dca32</gtr:id><gtr:otherNames>West EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/075DF6F0-76DB-4500-B29C-E05C4D760B6D"><gtr:id>075DF6F0-76DB-4500-B29C-E05C4D760B6D</gtr:id><gtr:title>Assessment of 180&amp;deg; rotation of the choroid as a novel surgical treatment for age-related macular degeneration.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8033763ccfe8bc587cd808477d8fa410"><gtr:id>8033763ccfe8bc587cd808477d8fa410</gtr:id><gtr:otherNames>Lee E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE7675A0-3952-4401-BAD8-97E964F9C96C"><gtr:id>AE7675A0-3952-4401-BAD8-97E964F9C96C</gtr:id><gtr:title>Induced pluripotent stem cell therapies for retinal disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/46122d28c5aa4d5b44567d509129a2b3"><gtr:id>46122d28c5aa4d5b44567d509129a2b3</gtr:id><gtr:otherNames>Comyn O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB2B1B9A-F614-4C84-ACE4-9DBCE26295CC"><gtr:id>DB2B1B9A-F614-4C84-ACE4-9DBCE26295CC</gtr:id><gtr:title>Pharmacological disruption of the outer limiting membrane leads to increased retinal integration of transplanted photoreceptor precursors.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26d7dfcefdd053a52abac2493b7dca32"><gtr:id>26d7dfcefdd053a52abac2493b7dca32</gtr:id><gtr:otherNames>West EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/12B2176B-5B09-477D-BF8C-9112A8F853A0"><gtr:id>12B2176B-5B09-477D-BF8C-9112A8F853A0</gtr:id><gtr:title>Variable phenotypes in patients diagnosed with idiopathic multifocal choroiditis.</gtr:title><gtr:parentPublicationTitle>Clinical &amp; experimental ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/65d065d343ffbde713025f674eedcdcf"><gtr:id>65d065d343ffbde713025f674eedcdcf</gtr:id><gtr:otherNames>MacLaren RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1442-6404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F0C10FC4-8D1D-46C0-A7AA-B9777050A404"><gtr:id>F0C10FC4-8D1D-46C0-A7AA-B9777050A404</gtr:id><gtr:title>Stickler syndrome.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d3e88c9df00dab06ac6ada9981b00fc4"><gtr:id>d3e88c9df00dab06ac6ada9981b00fc4</gtr:id><gtr:otherNames>Aylward B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A6C94F96-1492-429A-95A8-B9279E0C6B8B"><gtr:id>A6C94F96-1492-429A-95A8-B9279E0C6B8B</gtr:id><gtr:title>Non-viral retinal gene therapy: a review.</gtr:title><gtr:parentPublicationTitle>Clinical &amp; experimental ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6bc4d3a687571427a227cdf50552869e"><gtr:id>6bc4d3a687571427a227cdf50552869e</gtr:id><gtr:otherNames>Charbel Issa P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1442-6404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/83586F83-8770-4A70-A2EE-23A5276F7E0C"><gtr:id>83586F83-8770-4A70-A2EE-23A5276F7E0C</gtr:id><gtr:title>Comparative analysis of progenitor cells isolated from the iris, pars plana, and ciliary body of the adult porcine eye.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/db4a78c379c4b08c18658287aaa1502b"><gtr:id>db4a78c379c4b08c18658287aaa1502b</gtr:id><gtr:otherNames>MacNeil A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36213E36-1A3A-42AD-A735-CA1DE41871A5"><gtr:id>36213E36-1A3A-42AD-A735-CA1DE41871A5</gtr:id><gtr:title>Neuroprotective gene therapy for the treatment of inherited retinal degeneration.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64f94d6bab9e907972bd284e2e8d429c"><gtr:id>64f94d6bab9e907972bd284e2e8d429c</gtr:id><gtr:otherNames>Buch PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6D0CF227-0206-4D6A-B202-5C941C2C4C56"><gtr:id>6D0CF227-0206-4D6A-B202-5C941C2C4C56</gtr:id><gtr:title>Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c97680faf9bd93b5fe8d5a65f85ac8af"><gtr:id>c97680faf9bd93b5fe8d5a65f85ac8af</gtr:id><gtr:otherNames>Tolmachova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5A1B8A8E-4889-44E2-97DA-82BF56D53ADE"><gtr:id>5A1B8A8E-4889-44E2-97DA-82BF56D53ADE</gtr:id><gtr:title>Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice.</gtr:title><gtr:parentPublicationTitle>The journal of gene medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d2be9c3cb1bb719bf5d558ae7010f024"><gtr:id>d2be9c3cb1bb719bf5d558ae7010f024</gtr:id><gtr:otherNames>Barker SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1099-498X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601588</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>78E3B265-B307-4D06-9AB7-1F69471E721F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>